Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY

Start Learning

Touch Loading image
Inflammation of the breast in women. Female breasts with signs of the disease. A low-poly construction of interconnected lines and points. Blue background.
JOURNALS
Start Learning
Gauging the Online Public Interest in Breast Cancer in Pakistan
touchIN CONVERSATION
Start Learning
Harnessing the power of precision medicine for the treatment of colorectal cancer
CE/CME ACCREDITED
JOURNALS
Start Learning
Shaping the future of cancer surgery: An interview with Professor Geerard Beets
JOURNALS
Start Learning
SARS-CoV-2 mRNA vaccination associated with increased survival in patients with lung cancer and melanoma treated with immune checkpoint inhibitors
touchEXPERT FOCUS
Start Learning
Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life
CE/CME ACCREDITED
JOURNALS
Start Learning
A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non–Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy
JOURNALS
Start Learning
Welcome to our new Editorial Board members!
JOURNALS
Start Learning
ESMO Congress 2024 – 13 – 17 September, Barcelona Spain
touchPANEL DISCUSSION
Start Learning
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
CE/CME ACCREDITED
JOURNALS
Start Learning
Project Cure CRC Awards Nearly $5 Million to Accelerate Advancements in Care

to view Favourites, Keep Notes and Track CME Credits

Favourites
Focused insights: Data implications of ADCs in NSCLC treatment
View
12 million reasons for action: Transforming cancer care for women
View
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
View
Capivasertib + paclitaxel for metastatic triple-negative breast cancer did not meet threshold for improving overall survival
View
Nivolumab plus Relatlimab alongside chemotherapy demonstrated improved clinical benefit in the RELATIVITY-104 trial
View
Looking to the future in the treatment of steroid-refractory chronic GvHD
View
Breast cancer highlights: DESTINY-Breast06, postMONARCH, TBCRC 048
View
Advances in GVHD: Highlights from EBMT 2024
View
Durvalumab for the Treatment of Advanced Biliary Tract Cancer
View
Knowledge for nurses: ADC updates in breast cancer
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup